Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV

Journal of Clinical Investigation

Volumn 96, Issue 5, 1995, Pages 2515-2520

  Kerins, David M ^a   Hao, Qin ^a   Vaughan, Douglas E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

angiotensin; endothelium; fibrinolysis; plasminogen activator inhibitor 1; renin angiotensin system; vascular

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; AMASTATIN; ANGIOTENSIN; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN RECEPTOR; BESTATIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEXAPEPTIDE; LOSARTAN POTASSIUM; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; WSU 1291;

ANIMAL CELL; ARTICLE; CATTLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBRINOLYSIS; GENE EXPRESSION; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOSIS;

EID: 0028802190     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118312     Document Type: Article

References (31)

1. van Mourik, J. A., D. A. Lawrence, and D. J. Loskutoff. 1984. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J. Biol. Chem. 259:14914-14921.
2. Sawdey, M., T. J. Podor, and D. J. Loskutoff. 1989. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells: induction by transforming growth factor-β, lipopolysaccharide and tumor necrosis factor. J. Biol. Chem. 264:10396-10401.
3. Gelehrter, T. D., and R. Sznycer-Laszuk. 1986. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J. Clin. Invest. 77:165-169.
4. Dichek, D., and T. Quertermous. 1989. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood. 74:222-228.
5. Gavras, H., J. J. Brown, A. F. Lever, R. F. MacAdam, and J. I. S. Robertson. 1971. Acute renal failure, tubular necrosis and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet. 2:19-22.
6. Gavras, H. 1994. Angiotensin-converting enzyme inhibition and the heart. Hypertension (Dallas). 23:813-818.
7. Olson, J. A., K. T. Shiverick, S. Ogilvie, W. C. Buhi, and M. K. Raizada. 1991. Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Proc. Natl. Acad. Sci. USA. 88:1928-1932.
8. Ridker, P. M., C. L. Gaboury, P. R. Conlin, E. W. Seely, G. H. Williams, and D. E. Vaughan. 1993. Stimulation of plasminogen activator inhibitor (PAI- 1) in vivo by infusion of angiotensin II. Circulation. 87:1969-1973.
9. Wright, R. A., A. D. Flapan, K. G. M. M. Alberti, C. A. Ludlam, and K. A. A. Fox. 1994. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J. Am. Coll. Cardiol. 24:67-73.
10. van Leeuwen, R. T., A. Kol, F. Andreotti, C. Kluft, A. Maseri, and G. Sperti. 1994. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation. 90:362-368.
11. Vaughan, D. E., S. A. Lazos, and K. Tong. 1995. Angiotensin II regulates mediates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J. Clin. Invest. 95:995-1001.
12. Harding, J. W., V. L. Cook, A. V. Miller-Wing, J. M. Hanesworth, M. F. Sardinia, K. L. Hall, J. W. Stobb, G. N. Swanson, J. K. Coleman, J. W. Wright, and E. C. Harding. 1992. Identification of an AII(3-8) [AIV] binding site in guinea pig hippocampus. Brain Res. 583:340-343.
13. Miller-Wing, A. V., J. M. Hanesworth, M. F. Sardinia, K. L. Hall, J. W. Wright, R. C. Speth, K. L. Grove, and J. W. Harding. 1993. Central angiotensin IV binding sites: distribution and specificity in guinea pig brain. J. Pharmacol. Exp. Ther. 266:1718-1726.
14. Chaki, S., and T. Inagami. 1992. Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells. Biochem. Biophys. Res. Commun. 182:388-394.
15. Swanson, G. N., J. M. Hanesworth, M. F. Sardinia, J. K. F. Coleman, J. W. Wright, K. L. Hall, A. V. Miller-Wing, J. W. Stobb, V. I. Cook, E. C. Harding, and J. W. Harding. 1992. Discovery of a distinct binding site for angiotensin II(3-8), a putative angiotensin IV. Regul. Pept. 40:409-419.
16. 2 recognition sites in bovine adrenal cortex. Eur. J. Pharmacol. 219:319-322.
17. 4 receptor structure-binding relationship: N-terminal-modified angiotensin IV analogues. Peptides. 15:1399-1406.
18. Booyse, F. M., B. J. Sedlock, and M. E. Rafelson. 1975. Culture of arterial endothelial cells. Thromb. Diath. Haemorrh. 34:825-839.
19. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
20. Rich, D. H., B. J. Moon, and S. Harbeson. 1984. Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes. J. Med. Chem. 27:417-422.
21. Haberl, R. L., P. J. Decker, and K. M. Einhaupl. 1991. Angiotensin degradation products mediate endothelium-dependent dilation of rabbit brain arterioles. Circ. Res. 68:1621-1627.
22. Hall, K. L., J. M. Hanesworth, A. E. Ball, G. P. Felgenhauer, H. L. Hosick, and J. W. Harding. 1993. Identification and characterization of a novel angiotensin binding site in cultured vascular smooth muscle cells that is specific for the hexapeptide (3-8) fragment of angiotensin II, angiotensin IV. Regul. Pept. 44:225-232.
23. Hanesworth, J. M., M. F. Sardinia, L. T. Krebs, K. L. Hall, and J. W. Harding. 1993. Elucidation of a specific binding site for angiotensin II(3-8), angiotensin IV, in mammalian heart membranes. J. Pharmacol. Exp. Ther. 266:1036-1042.
24. Brazsko, J. J., G. Kupryszewski, B. Witczuk, and K. Wisniewski. 1988. Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats. Neuroscience. 27:777-783.
25. Ahmad, S., and P. E. Ward. 1990. Role of aminopeptidase activity in the regulation of the pressor activity of circulating angiotensins. J. Pharmacol. Exp. Ther. 252:643-650.
26. Pfeffer, M. A., E. Braunwald, L. A. Moye, L. Basta, E. J. Brown, T. E. Cuddy, B. R. Davis, E. M. Geltman, S. Goldman, G. G. Flaker, et al. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N. Engl. J. Med. 327:669-677.
27. Yusuf, S., C. J. Pepine, C. Garces, H. Pouleur, D. Salem, J. Kostis, C. Bened, M. Bourassa, and B. Pitt. 1992. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 340:1173-1178.
28. Rutherford, J. D., M. A. Pfeffer, L. A. Moye, B. R. Davis, G. C. Flaker, P. R. Kowey, G. A. Lamas, H. S. Miller, M. Packer, J. L. Rouleau, and E. Braunwald. 1994. Effects of captopril on ischemic events after myocardial infarction: results of the survival and ventricular enlargement trial. Circulation. 90:1731-1738.
29. Hamsten, A., G. Walldins, A. Szamosi, M. Blomback, U. deFaire, G. Dahlen, C. Landou, and B. Wiman. 1987. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 2:3-9.
30. Goldberg, M. R., W. Tanaka, A. Barchowsky, T. E. Bradstreet, J. McCrea, M.-W. Lo, E. J. McWilliams, and T. D. Bjornsson. 1993. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension (Dallas). 21:704-713.
31. Goldberg, M. R., T. E. Bradstreet, E. J. McWilliams, W. K. Tanaka, S. Lipert, T. D. Bjornsson, S. A. Waldman, B. Osborne, L. Pivadori, G. Lewis, et al. 1995. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension (Dallas). 25:37-46.